A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

Exclusion Criteria

• •Breastfeeding or pregnant.
• •BMI is 40 or higher (exceptions can be made if you're in good health).
• •Diagnosed with diabetes (unless it's well-controlled Type 2 diabetes or gestational diabetes).
• •Received an investigational HIV vaccine or monoclonal antibodies.
• •Received a non-HIV investigational vaccine in the past year (exceptions exist for licensed or emergency-authorized vaccines).
• •Have an immune deficiency or are taking medications that impair immune response.
• •Received blood products or immunoglobulins within the last 16 weeks.
• •Received certain vaccines within 4 weeks before enrollment.
• •Received other vaccines within 14 days before enrollment.
• •Started allergy immunotherapy within the last year (stable therapy is okay).
• •Taken investigational research agents recently.
• •Had a serious reaction to any vaccine.
• •Have hereditary or acquired angioedema.
• •Had unexplained hives in the past year.
• •Have a bleeding disorder that would make study procedures risky.
• •Had seizures or taken seizure medication in the past 3 years.
• •Spleen has been removed or spleen doesn't work properly.
• •Active duty or reserve US military personnel.
• •Any serious health condition that could affect safety, rights, or ability to participate (including substance use, psychiatric disorders, recent suicide attempts, or cancer with potential recurrence).
• •Asthma that requires frequent or high-dose medication, emergency care, or multiple maintenance therapies.
• •History of certain immune-mediated medical conditions (mild, localized conditions may be okay).
• •Allergic to local anesthetics like Novocaine or Lidocaine.
• •History of difficult venous access or intravenous drug use.